Cyproheptadine enhances weight gain and modulates appetite-regulating peptides in children with failure to thrive and food allergies
Frontiers in Pharmacology · 15.06.2026 · 17
DOI: 10.3389/fphar.2026.1776222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.06.2026. Verfasst von Yuxin Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Chi…. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Cyproheptadine hydrochloride (CH) possesses both antihistaminic and appetite-stimulating properties, suggesting therapeutic potential for children with failure to thrive (FTT) and food allergies. This study evaluated the effects of CH on growth parameters, clinical manifestations, and serum levels of appetite-regulating peptides Nesfatin-1 and NUCB2 in children aged 1–3 years with FTT and food allergy.
Methods
In this non-randomized controlled real-world study, participants were assigned to either the treatment group (T-group, n = 25), receiving CH at 0.15 mg/kg twice daily for 12 weeks, or the control group (NT-group, n = 19). Primary outcomes were anthropometric indices: body weight, weight-for-age Z-score (WAZ), height, weight-for-length Z-score (WLZ), body mass index (BMI), and length-for-age Z-score (LAZ). Secondary outcomes included clinical symptom scores and changes in Nesfatin-1 and NUCB2 levels.
Results
After 12 weeks, the T-group showed significantly greater improvements in body weight (10.32 ± 0.28 kg vs. 9.05 ± 0.23 kg, P = 0.002), WAZ ( P < 0.001), WLZ ( P < 0.001), and BMI ( P = 0.001) compared to the NT-group. No significant differences were observed in height or LAZ. Within the T-group, significant improvements from baseline to week 12 were observed for all weight-based indices ( P < 0.001). CH treatment was also associated with significant reductions in serum Nesfatin-1 ( P = 0.000) and NUCB2 ( P = 0.043) levels. At baseline, reduced food intake and sleep disturbances were negatively correlated with WAZ and LAZ, respectively.
Conclusion
CH treatment significantly enhances weight gain and improves key anthropometric indices in young children with FTT and food allergy, potentially mediated by the downregulation of anorexigenic peptides Nesfatin-1 and NUCB2. These findings suggest that CH may be a promising pharmacotherapeutic option for this complex patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Shenzhen Maternity and Child Healthcare Hospital, Women and Children's Medical Center, Southern Medical University, Shenzhen, Guangdong, China.
- Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, China.
Zitieren
APA
Zhang, Y., Ma, N., Lan, J., Zhang, X., Li, Z., Zhao, Q., Jin, C., Li, C., & Yang, M. (2026). Cyproheptadine enhances weight gain and modulates appetite-regulating peptides in children with failure to thrive and food allergies. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1776222
Vancouver
Zhang Y, Ma N, Lan J, Zhang X, Li Z, Zhao Q, et al. Cyproheptadine enhances weight gain and modulates appetite-regulating peptides in children with failure to thrive and food allergies. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1776222
BibTeX
@article{Zhang2026,
author = {Zhang, Yuxin and Ma, Ni and Lan, Jiaoli and Zhang, Xiaoyan and Li, Zhiling and Zhao, Qing and Jin, Cuiyuan and Li, Chunfu and Yang, Min},
title = {Cyproheptadine enhances weight gain and modulates appetite-regulating peptides in children with failure to thrive and food allergies},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1776222}
}
EUVIMED